Logo

American Heart Association

  2
  0


Final ID: Mo1107

Elucidation of a novel genetic substrate responsible for genetically elusive ring-like arrhythmogenic cardiomyopathy

Abstract Body (Do not enter title and authors here): Background: Arrhythmogenic cardiomyopathy (ACM) is a genetic heart disease characterized by fibrofatty replacement of ventricular myocardium. Arrhythmogenic left ventricular (LV) cardiomyopathy (ALVC) is a phenotypic variant of ACM predominantly involving the LV. Mutations in genes encoding for desmosome proteins and filamin C have been implicated in ALVC, especially in the setting of a ring-like late gadolinium enhancement (LGE) imaging pattern.

Objective: To identify the underlying genetic substrate responsible for genetically elusive ring-like ALVC in a patient with seemingly sporadic/recessive disease.

Methods: A 38-year-old male was referred for genetic investigation to determine the underlying genetic substrate responsible for his ALVC phenotype. The patient fulfilled both electrocardiographic (low voltage in the limb leads and anterolateral T-wave inversions) and imaging (>1 segment of subepicardial LGE) criteria for ALVC. Additionally, the patient experienced unexplained episodes of tachycardia, shakiness, sweating, and nausea prompting concern for an underlying neuromuscular disease. Genome sequencing (GS) was performed on DNA isolated from the affected patient and both of his unaffected parents. Variants were filtered assuming either a sporadic de novo occurrence or an autosomal recessive inheritance pattern.
Results: GS identified compound heterozygous GNPTAB variants in the affected patient. A previously reported maternally derived p.Leu257Leu (c.771G>A) variant involving the last nucleotide of exon 7 of the GNPTAB gene and a novel paternally inherited Lys834fs*5 frame-shift variant were identified. The p.Leu257Leu variant has been reported to cause aberrant splicing and exon skipping of the GNPTAB mRNA transcript. Pathogenic variants in the GNPTAB encoded N-acetylglucosamine-1 (GlcNAc)-phosphotransferase subunits alpha/beta cause mucolipidosis type III, a rare recessive lysosomal storage disease characterized by coarse facial features, developmental delay, short stature, skeletal deformities, and cardiac involvement including valvular thickening and cardiomyopathy.

Conclusions: Here, using a genome sequencing trio analysis we identified a compound heterozygous GNPTAB pathogenic variants as the underlying genetic substrate in a patient with ring-like ALVC and concomitant neuromuscular disease manifestation. Genome sequencing may identify the genetic etiology responsible for an otherwise undifferentiated diagnosis of cardiomyopathy.
  • Tester, David  ( MAYO CLINIC COLLEGE OF MEDICINE , Rochester , Minnesota , United States )
  • Castrichini, Matteo  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Ackerman, Michael  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Giudicessi, John  ( Mayo Clinic , Rochester , Minnesota , United States )
  • Author Disclosures:
    David Tester: DO NOT have relevant financial relationships | Matteo Castrichini: DO NOT have relevant financial relationships | Michael Ackerman: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Royalties/Patent Beneficiary:Thryv Therapeutics:Active (exists now) ; Royalties/Patent Beneficiary:Pfizer:Past (completed) ; Royalties/Patent Beneficiary:ARMGO Pharma:Active (exists now) ; Royalties/Patent Beneficiary:Anumana:Active (exists now) ; Royalties/Patent Beneficiary:AliveCor:Active (exists now) ; Consultant:Tenaya Therapeutics:Active (exists now) ; Consultant:Solid Biosciences:Active (exists now) ; Consultant:Medtronic:Active (exists now) ; Consultant:Invitae:Active (exists now) ; Consultant:Illumina:Active (exists now) ; Consultant:Daiichi Sankyo:Past (completed) ; Consultant:Bristol Myers Squibb:Active (exists now) ; Consultant:Boston Scientific:Active (exists now) ; Consultant:BioMarin Pharmaceutical:Active (exists now) | John Giudicessi: DO have relevant financial relationships ; Consultant:Avidity Biosciences:Active (exists now) ; Other (please indicate in the box next to the company name):Prolaio (equity/royalty sharing):Active (exists now) ; Research Funding (PI or named investigator):Tenaya Therapeutics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Heart Failure Must See CV (Clinical Vignettes)

Monday, 11/18/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts on this topic:
Notch3 and the Vascular-Adipose Interactome in the Regulation of Adiponectin and Vascular Contraction

Montezano Augusto, Touyz Rhian, Sarafian Raquel, Rao Prashant, He Ying, Rios Francisco, Camargo Livia, Chen Zsu-zsu, Barber Jacob, Gerszten Robert

Can the reduction of mutant endothelial cells hold promise for treating brain arteriovenous malformation?

Shabani Nabikandi Zahra, Prado Leandro, Shaligram Sonali, Zhang Rui, Zhu Wan, Liang Rich, Yadav Alka, Wang Calvin, Su Hua

More abstracts from these authors:
Prevalence, Genetic Correlates and Prognostic Significance of an Apical Pseudo-Infarct Late Gadolinium Enhancement Pattern in LMNA-Mediated Cardiac Laminopathy

Castrichini Matteo, Garmany Ramin, Siontis Konstantinos, Ackerman Michael, Giudicessi John

Prognostic Significance of Exercise-Induced Ventricular Arrhythmia Patterns in PKP2-Mediated Arrhythmogenic Cardiomyopathy

Castrichini Matteo, Neves Raquel, Garmany Ramin, Allison Thomas, Ackerman Michael, Giudicessi John

You have to be authorized to contact abstract author. Please, Login
Not Available